RS56232B1 - Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene - Google Patents

Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene

Info

Publication number
RS56232B1
RS56232B1 RS20170700A RSP20170700A RS56232B1 RS 56232 B1 RS56232 B1 RS 56232B1 RS 20170700 A RS20170700 A RS 20170700A RS P20170700 A RSP20170700 A RS P20170700A RS 56232 B1 RS56232 B1 RS 56232B1
Authority
RS
Serbia
Prior art keywords
mmol
mixture
chh
oxo
stirred
Prior art date
Application number
RS20170700A
Other languages
English (en)
Serbian (sr)
Inventor
Hon-Wah Man
George W Muller
Alexander Ruchelman
Ehab M Khalil
Roger Shen-Chu Chen
Weihong Zhang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of RS56232B1 publication Critical patent/RS56232B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
RS20170700A 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene RS56232B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30361810P 2010-02-11 2010-02-11
PCT/US2011/024269 WO2011100380A1 (en) 2010-02-11 2011-02-10 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Publications (1)

Publication Number Publication Date
RS56232B1 true RS56232B1 (sr) 2017-11-30

Family

ID=43708752

Family Applications (3)

Application Number Title Priority Date Filing Date
RS20170700A RS56232B1 (sr) 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
RS20190249A RS58523B1 (sr) 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
RSP20190965 RS59275B1 (sr) 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene

Family Applications After (2)

Application Number Title Priority Date Filing Date
RS20190249A RS58523B1 (sr) 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
RSP20190965 RS59275B1 (sr) 2010-02-11 2011-02-10 Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene

Country Status (33)

Country Link
US (8) US8518972B2 (enExample)
EP (6) EP3599236B1 (enExample)
JP (5) JP2013519675A (enExample)
KR (2) KR101812356B1 (enExample)
CN (2) CN104693193B (enExample)
AR (1) AR081058A1 (enExample)
AU (1) AU2011215877C1 (enExample)
CA (1) CA2787823C (enExample)
CO (1) CO6571916A2 (enExample)
CR (1) CR20120414A (enExample)
CY (3) CY1119177T1 (enExample)
DK (3) DK2536706T3 (enExample)
EC (1) ECSP12012098A (enExample)
ES (5) ES2713482T3 (enExample)
HR (3) HRP20171078T1 (enExample)
HU (3) HUE042011T2 (enExample)
IL (2) IL220992A (enExample)
LT (3) LT3202461T (enExample)
ME (2) ME02766B (enExample)
MX (3) MX2012009237A (enExample)
NI (1) NI201200132A (enExample)
NZ (3) NZ601289A (enExample)
PH (2) PH12012501607A1 (enExample)
PL (3) PL2536706T3 (enExample)
PT (3) PT3202461T (enExample)
RS (3) RS56232B1 (enExample)
RU (1) RU2567753C2 (enExample)
SG (3) SG10202012179RA (enExample)
SI (3) SI2536706T1 (enExample)
SM (3) SMT201900155T1 (enExample)
TR (1) TR201903027T4 (enExample)
UA (2) UA115220C2 (enExample)
WO (1) WO2011100380A1 (enExample)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
PL2536706T3 (pl) 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
MX353482B (es) 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
CA3136093C (en) 2012-06-29 2025-07-08 Celgene Corporation METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
US20140343058A1 (en) * 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
SG11201500984QA (en) * 2012-08-09 2015-04-29 Celgene Corp Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
RS58548B1 (sr) * 2012-08-09 2019-05-31 Celgene Corp Čvrsta forma (s)-3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidrohlorida
JP6347782B2 (ja) * 2012-08-09 2018-06-27 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
PT2882441T (pt) * 2012-08-09 2020-06-29 Celgene Corp Tratamento de doenças associadas à imunidade e inflamatórias
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CA2884103A1 (en) * 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
AU2014254056B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
UA117141C2 (uk) * 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112016012795A2 (pt) * 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6778114B2 (ja) * 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
ES2969532T3 (es) 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
SMT202300081T1 (it) 2014-08-22 2023-05-12 Celgene Corp Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX390189B (es) 2015-01-20 2025-03-20 Arvinas Operations Inc COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs.
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
KR102660070B1 (ko) * 2015-07-21 2024-04-24 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체의 제조 방법
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR102053556B1 (ko) * 2015-09-29 2020-01-08 강푸 바이오파마슈티칼즈 리미티드 약물 조성물 및 이의 응용
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
AU2017246453A1 (en) * 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
BR112018070859A2 (pt) * 2016-04-12 2019-02-05 Univ Michigan Regents degradantes da proteína de bet
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
IL318681A (en) 2016-10-11 2025-03-01 Arvinas Operations Inc Compounds and methods for targeted reduction of androgen receptor
JP2019537585A (ja) * 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Ｅｚｈ２媒介性がんを治療するための組成物および方法
AU2017367872B2 (en) 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CN118834201A (zh) 2016-12-01 2024-10-25 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
CA3045037A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
KR20220028178A (ko) * 2016-12-16 2022-03-08 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
KR20190101406A (ko) 2016-12-23 2019-08-30 아비나스 오퍼레이션스, 인코포레이티드 Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR102839545B1 (ko) 2016-12-23 2025-07-29 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CA3049912A1 (en) 2017-01-26 2018-08-02 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
EP3573979A1 (en) 2017-01-27 2019-12-04 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
EP3577459A4 (en) 2017-02-03 2020-12-16 Celgene Corporation METHOD OF MEASURING THE AFFINITY OF SMALL MOLECULES FOR CEREBLON
CA3053805C (en) 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
WO2019014100A1 (en) * 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
CA3072735A1 (en) 2017-08-21 2019-02-28 Celgene Corporation Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019211910B2 (en) 2018-01-25 2022-09-22 Fujimoto Co., Ltd Thiophene derivative and use thereof
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
US11401336B2 (en) 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
SG11202009237XA (en) * 2018-04-23 2020-10-29 Celgene Corp Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
JP2021527666A (ja) 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
BR112020026450A2 (pt) 2018-06-29 2021-03-23 F. Hoffmann-La Roche Ag Compostos de fórmula i
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2020048546A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环取代哌啶二酮类化合物
WO2020064002A1 (zh) 2018-09-30 2020-04-02 中国科学院上海药物研究所 异吲哚啉类化合物、其制备方法、药物组合物及用途
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP3891128A4 (en) * 2018-12-05 2022-08-17 Vividion Therapeutics, Inc. SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT
CN111285850B (zh) * 2018-12-06 2022-04-22 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
EA202191903A1 (ru) 2019-01-09 2021-11-12 Селджин Корпорейшн Антипролиферативные соединения и вторые активные агенты для комбинированного применения
CA3126067A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
SG11202107439XA (en) * 2019-01-09 2021-08-30 Celgene Corp Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
MX2021015995A (es) 2019-06-28 2022-03-11 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN114867727B (zh) 2019-07-17 2025-02-21 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN112321566B (zh) 2019-08-05 2022-06-10 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
IL290789B2 (en) 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN119019369A (zh) 2019-10-17 2024-11-26 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
CN114929686A (zh) * 2019-10-21 2022-08-19 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮及其盐的固体形式，以及含有其的组合物及它们的用途
US20210128619A1 (en) 2019-11-05 2021-05-06 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
US20220401483A1 (en) 2019-11-07 2022-12-22 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
AU2020392427B2 (en) 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
US20230065745A1 (en) 2019-11-27 2023-03-02 Captor Therapeutics S.A. Piperidine-2,6-dione derivatives which bind to cereblon, and methods of use thereof
CN115315260A (zh) 2019-12-02 2022-11-08 新基公司 治疗癌症的疗法
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3835298B1 (en) * 2019-12-12 2024-06-26 Accutar Biotechnology Inc. Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
CN115052627A (zh) * 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
CA3164832A1 (en) * 2019-12-18 2021-06-24 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
JP7408819B2 (ja) * 2020-01-20 2024-01-05 カング バイオファーマシューティカルズ リミテッド イソインドリン誘導体、並びにその医薬組成物及び使用
KR102833592B1 (ko) * 2020-02-25 2025-07-15 상하이테크 유니버시티 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US20230172923A1 (en) 2020-04-30 2023-06-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
TW202208345A (zh) 2020-05-09 2022-03-01 美商亞文納營運公司 雙官能性化合物的製造方法、該雙官能性化合物的超純形式、及含彼之劑型
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
BR112022026090A2 (pt) 2020-06-25 2023-01-17 Celgene Corp Métodos para tratar câncer com terapias de combinação
CN113896711A (zh) * 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
JP2023534528A (ja) * 2020-07-20 2023-08-09 江蘇恒瑞医薬股▲ふん▼有限公司 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用
WO2022029138A1 (en) 2020-08-03 2022-02-10 Captor Therapeutics S.A. Low molecular weight protein degraders and their applications
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
IL301048A (en) 2020-09-11 2023-05-01 Bristol Myers Squibb Co Combination therapy for cancer
KR20230069144A (ko) 2020-09-14 2023-05-18 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
WO2022066580A1 (en) * 2020-09-23 2022-03-31 Kinnate Biopharma Inc. Raf degrading compounds
CN116234553A (zh) * 2020-10-02 2023-06-06 新基公司 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途
EP4241278A2 (en) 2020-11-04 2023-09-13 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CN112174976A (zh) * 2020-11-19 2021-01-05 江西中医药大学 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途
WO2022146151A1 (en) 2020-12-30 2022-07-07 Captor Therapeutics S.A. Novel compounds which bind to cereblon, and methods of use thereof
CA3202360A1 (en) 2020-12-30 2022-07-07 Nello Mainolfi Irak degraders and uses thereof
CN116669736B (zh) * 2021-01-05 2025-11-11 江苏恒瑞医药股份有限公司 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
CA3207049A1 (en) 2021-02-15 2022-08-18 Jared Gollob Irak4 degraders and uses thereof
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
UY39671A (es) * 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
JP7768592B2 (ja) * 2021-03-31 2025-11-12 デューク ストリート バイオ リミテッド 医薬化合物
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
WO2022255889A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2022255890A1 (en) 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
UY39796A (es) 2021-06-03 2023-07-31 Novartis Ag Derivados de 3–((5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023025136A1 (zh) * 2021-08-27 2023-03-02 杭州格博生物医药有限公司 异吲哚啉酮化合物及其用途
EP4395549A1 (en) * 2021-09-01 2024-07-10 Oerth Bio LLC Compositions and methods for targeted degradation of proteins in a plant cell
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
US20250154126A1 (en) * 2022-01-19 2025-05-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfur-containing isoindoline derivative
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115160211B (zh) * 2022-06-23 2023-11-03 温州大学 一种异吲哚啉酮类化合物的绿色合成方法
EP4545524A1 (en) * 2022-06-24 2025-04-30 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Substituted 4-aminoisoindoline compound, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
EP4611798A1 (en) 2022-11-02 2025-09-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4619399A1 (en) 2022-11-16 2025-09-24 Basf Se New substituted tetrahydrobenzoxazepine
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
WO2024167423A1 (en) 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025120113A1 (en) 2023-12-08 2025-06-12 Celgene Corporation Therapy for the treatment of multiple myeloma
US12496301B2 (en) 2023-12-08 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) * 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5149820A (en) * 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1994007498A1 (fr) * 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ES2243052T3 (es) * 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
EP1182681B1 (en) 2000-08-23 2006-03-01 General Electric Company Injection molded ceramic metal halide arc tube having non-tapered end
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CN1981761B (zh) 2002-05-17 2011-10-12 细胞基因公司 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1694328A4 (en) 2003-12-02 2010-02-17 Celgene Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
NZ550026A (en) 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
AU2005237490A1 (en) 2004-04-23 2005-11-10 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
BRPI0418798A (pt) 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit
BRPI0513433A (pt) 2004-07-16 2008-05-06 Schering Corp derivados de hidantoìna para o tratamento de distúrbios inflamatórios
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
KR20070086000A (ko) 2004-11-12 2007-08-27 셀진 코포레이션 기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물
MX2007006063A (es) 2004-11-23 2007-07-11 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
CN101111234A (zh) 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
RS52704B (sr) 2005-06-30 2013-08-30 Celgene Corporation Postupci za dobijanje 4-amino-2-(2,6-dioksopiperidin-3-il) izoindolin-1,3-dionskih jedinjenja
BRPI0614995A2 (pt) * 2005-08-31 2010-01-12 Celgene Corp composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
RU2009114159A (ru) 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
US20110184025A1 (en) 2006-10-19 2011-07-28 Hensel Jennifer L Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases
KR101791757B1 (ko) * 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
PL2536706T3 (pl) * 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA3136093C (en) 2012-06-29 2025-07-08 Celgene Corporation METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
JP6347782B2 (ja) 2012-08-09 2018-06-27 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
SG11201500984QA (en) 2012-08-09 2015-04-29 Celgene Corp Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
RS58548B1 (sr) 2012-08-09 2019-05-31 Celgene Corp Čvrsta forma (s)-3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidrohlorida
PT2882441T (pt) 2012-08-09 2020-06-29 Celgene Corp Tratamento de doenças associadas à imunidade e inflamatórias
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CA2884103A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
BR112015020584A2 (pt) 2013-03-14 2017-07-18 Celgene Corp métodos para o tratamento de artrite psoriática usando apremilast
AU2014254056B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2969532T3 (es) 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
WO2016025686A1 (en) 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US20170242014A1 (en) 2014-10-13 2017-08-24 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
NZ731789A (en) 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
AU2011215877A1 (en) 2012-08-16
JP2017200944A (ja) 2017-11-09
SMT201900155T1 (it) 2019-05-10
CN102822165A (zh) 2012-12-12
HRP20191312T1 (hr) 2019-10-18
EP3202461A1 (en) 2017-08-09
KR20130010888A (ko) 2013-01-29
JP2016172746A (ja) 2016-09-29
EP3202460B1 (en) 2019-06-12
DK2536706T3 (en) 2017-08-14
ES2638517T3 (es) 2017-10-23
LT3202461T (lt) 2019-04-25
KR101812356B1 (ko) 2017-12-26
NZ601289A (en) 2014-10-31
HUE044652T2 (hu) 2019-11-28
US20180037567A1 (en) 2018-02-08
MX367522B (es) 2019-08-26
RS59275B1 (sr) 2019-10-31
PT3202461T (pt) 2019-03-19
PH12014501082B1 (en) 2015-09-28
SMT201700360T1 (it) 2017-09-07
JP2016106106A (ja) 2016-06-16
EP2536706B1 (en) 2017-06-14
US20220411402A1 (en) 2022-12-29
RU2012138709A (ru) 2014-03-20
HRP20190368T1 (hr) 2019-04-19
SG183257A1 (en) 2012-09-27
AR081058A1 (es) 2012-06-06
US8518972B2 (en) 2013-08-27
ES2713482T3 (es) 2019-05-22
AU2011215877B2 (en) 2013-11-07
ECSP12012098A (es) 2012-10-30
LT3202460T (lt) 2019-10-10
CN102822165B (zh) 2015-02-25
NZ717149A (en) 2017-06-30
IL248843B (en) 2019-12-31
TR201903027T4 (tr) 2019-03-21
JP6215976B2 (ja) 2017-10-18
US20200231567A1 (en) 2020-07-23
US9309219B2 (en) 2016-04-12
US9822094B2 (en) 2017-11-21
ES2738776T3 (es) 2020-01-27
DK3202460T3 (da) 2019-07-29
ME03441B (me) 2020-01-20
SG10202012179RA (en) 2021-01-28
UA115220C2 (uk) 2017-10-10
ES2730763T3 (es) 2019-11-12
CY1121729T1 (el) 2020-07-31
HUE042011T2 (hu) 2019-06-28
IL248843A0 (en) 2017-01-31
US20160159772A1 (en) 2016-06-09
UA114856C2 (uk) 2017-08-10
SI2536706T1 (sl) 2017-10-30
CY1121858T1 (el) 2020-10-14
SMT201900420T1 (it) 2019-11-13
AU2011215877C1 (en) 2017-01-19
IL220992A (en) 2016-11-30
EP4289838A3 (en) 2024-03-13
PL3202461T3 (pl) 2019-07-31
EP2536706A1 (en) 2012-12-26
EP3106460A1 (en) 2016-12-21
CN104693193B (zh) 2018-09-18
RU2567753C2 (ru) 2015-11-10
NZ700054A (en) 2016-03-31
PH12014501082A1 (en) 2015-09-28
US10189814B2 (en) 2019-01-29
ES2956743T3 (es) 2023-12-27
SI3202460T1 (sl) 2019-10-30
CA2787823C (en) 2018-04-10
US20130324518A1 (en) 2013-12-05
US20190135780A1 (en) 2019-05-09
EP3202460A1 (en) 2017-08-09
EP3599236A1 (en) 2020-01-29
JP2013519675A (ja) 2013-05-30
PH12012501607A1 (en) 2012-10-22
US20110196150A1 (en) 2011-08-11
US9828361B2 (en) 2017-11-28
EP3202461B1 (en) 2018-12-26
US11414399B2 (en) 2022-08-16
CA2787823A1 (en) 2011-08-18
US10669257B2 (en) 2020-06-02
EP4289838A2 (en) 2023-12-13
HRP20171078T1 (hr) 2017-10-06
PL3202460T3 (pl) 2019-12-31
JP2017031165A (ja) 2017-02-09
CN104693193A (zh) 2015-06-10
JP6270944B2 (ja) 2018-01-31
MX337169B (es) 2016-02-16
NI201200132A (es) 2013-04-22
DK3202461T3 (en) 2019-03-18
RS58523B1 (sr) 2019-04-30
KR20180000338A (ko) 2018-01-02
PT2536706T (pt) 2017-07-20
ME02766B (me) 2018-01-20
EP3106460B1 (en) 2019-04-10
US20160159768A1 (en) 2016-06-09
EP3599236B1 (en) 2023-08-23
SG10201501062SA (en) 2015-04-29
MX2012009237A (es) 2012-08-23
PT3202460T (pt) 2019-08-05
HUE033009T2 (en) 2017-11-28
SI3202461T1 (sl) 2019-05-31
CO6571916A2 (es) 2012-11-30
KR101931468B1 (ko) 2018-12-20
PL2536706T3 (pl) 2017-10-31
WO2011100380A1 (en) 2011-08-18
CY1119177T1 (el) 2018-02-14
LT2536706T (lt) 2017-10-25
CR20120414A (es) 2012-10-31

Similar Documents

Publication Publication Date Title
US11414399B2 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK40105123A (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2016203826A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK40020802A (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK40020802B (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1242245B (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1242246A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1242245A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1242246B (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1231872A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1179604B (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
HK1179604A (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same